The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis
Background Respiratory syncytial virus (RSV), a common respiratory pathogen, can lead to severe symptoms, especially in older adults (OA). A recently developed RSV prefusion F protein (RSVPreF3 OA) vaccine confers high protection against RSV lower respiratory tract disease (LRTD) over two full RSV s...
Main Authors: | Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2323128 |
Similar Items
-
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
by: Akiko Mizukami, et al.
Published: (2024-12-01) -
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
by: Antonios O. Aliprantis, et al.
Published: (2021-05-01) -
RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
by: Freek Cox, et al.
Published: (2023-03-01) -
Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
by: Pramila Lamichhane, et al.
Published: (2022-11-01) -
Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis Using Prefusion F and G Protein Antibodies
by: Eliel Nham, et al.
Published: (2024-05-01)